Skip to main content
    T

    Twist Bioscience Corp (TWST)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $105.04
    -6.56 (-5.88%)

    Market Cap: $7.40B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Twist Bioscience Corp (TWST) Financials: Revenue, Profit and Cash Flow

    Updated Nov 12, 2026. Financial statements from company filings, amounts in US dollars.

    Twist Bioscience reported revenue of $459.43M for the fiscal year ended Sep 30, 2026, up 22.0% from the year before. That year, net income was -$130.20M with a net margin of -28.3%, operating cash flow was -$41.43M and free cash flow was -$89.01M. The quarter ended Sep 30, 2026 had revenue of $126.64M and net income of -$20.62M.

    Revenue and Margins

    The operating margin was -30.4% in the fiscal year ended Sep 2026, the highest of the 4 years shown with an operating margin. Over the 9 years to Sep 2026, revenue grew from $10.77M, a compound annual rate of 51.7%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Sep 2026$459.43M+22.0%52.4%-30.4%-28.3%
    Sep 2025$376.57M+20.3%50.7%-36.2%-20.6%
    Sep 2024$312.97M+27.7%42.6%-70.6%-66.7%
    Sep 2023$245.11M+20.4%36.6%-88.6%-83.5%
    Sep 2022$203.56M+53.8%41.4%-115.3%-107.0%
    Sep 2021$132.33M+46.9%39.1%-115.4%-114.9%
    Sep 2020$90.10M+65.7%31.8%-155.5%-155.3%
    Sep 2019$54.38M+113.9%12.8%-200.1%-198.0%
    Sep 2018$25.43M+136.2%-26.6%-277.5%-280.2%
    Sep 2017$10.77MN/A-123.1%-543.2%-550.8%
    Annual, fiscal years ended Sep 2017 to Sep 2026

    Income Statement

    In the fiscal year ended Sep 2026, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemSep 2026Sep 2025Sep 2024Sep 2023Sep 2022Sep 2021Sep 2020Sep 2019Sep 2018Sep 2017
    Revenue$459.43M$376.57M$312.97M$245.11M$203.56M$132.33M$90.10M$54.38M$25.43M$10.77M
    Cost of revenue$218.63M$185.57M$179.63M$155.38M$119.33M$80.62M$61.41M$47.43M$32.19M$24.02M
    Gross profit$240.80M$191.00M$133.35M$89.73M$84.23M$51.71M$28.69M$6.96M-$6.76M-$13.25M
    Research and development$71.84M$80.28M$90.85M$106.89M$120.31M$69.07M$43.01M$35.68M$20.35M$19.17M
    Operating income-$139.46M-$136.26M-$220.83M-$217.16M-$234.78M-$152.73M-$140.08M-$108.85M-$70.56M-$58.48M
    Net income-$130.20M-$77.67M-$208.73M-$204.62M-$217.86M-$152.10M-$139.93M-$107.67M-$71.24M-$59.31M
    EBITDA-$112.12M-$63.46M-$192.08M-$188.52M-$219.35M-$144.88M-$133.61M-$103.97M-$64.64M-$53.42M
    Fiscal years ended Sep 2017 to Sep 2026

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$126.64M$118.38M$110.72M$103.70M$99.01M$96.06M$92.79M$88.71M$84.71M$81.46M$75.30M$71.50M
    Gross profit$67.25M$62.45M$57.12M$53.97M$50.84M$51.30M$46.03M$42.84M$38.23M$35.27M$30.88M$28.96M
    Operating income-$24.41M-$36.28M-$45.86M-$32.90M-$29.93M-$30.12M-$41.56M-$34.64M-$36.04M-$88.92M-$48.89M-$46.98M
    Net income-$20.62M-$35.05M-$44.02M-$30.51M-$27.14M$20.39M-$39.33M-$31.59M-$34.66M-$85.57M-$45.49M-$43.01M
    Last 12 quarters

    Balance Sheet

    As of Sep 2026, cash and equivalents of $533.99M were 47.7% of total assets of $1.12B, against total liabilities of $233.79M.

    Annual

    Line itemSep 2026Sep 2025Sep 2024Sep 2023Sep 2022Sep 2021Sep 2020Sep 2019Sep 2018Sep 2017
    Total assets$1.12B$641.86M$614.32M$776.40M$961.38M$702.10M$398.88M$186.99M$115.79M$85.66M
    Current assets$737.22M$332.97M$346.78M$424.26M$596.48M$546.50M$334.87M$160.13M$95.67M$67.87M
    Cash and equivalents$533.99M$183.05M$226.32M$286.47M$378.69M$465.83M$93.67M$46.73M$80.76M$31.23M
    Total liabilities$233.79M$168.90M$141.63M$152.97M$171.99M$121.28M$62.62M$34.91M$26.73M$219.01M
    Short-term debtN/A$13.82M$14.80M$14.90M$13.64M$1.55M$3.33M$3.33M$2.50M$9.15M
    Long-term debtN/AN/AN/AN/AN/AN/A$1.40M$4.40M$7.22M$9.15M
    Shareholder equity$888.02M$472.96M$472.69M$623.43M$789.38M$580.82M$336.26M$152.08M-$201.42M-$133.36M
    Fiscal years ended Sep 2017 to Sep 2026

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$1.12B$672.44M$676.21M$638.09M$641.86M$643.61M$595.62M$608.58M$614.32M$638.12M$702.85M$732.82M
    Total liabilities$233.79M$226.70M$221.12M$181.99M$168.90M$165.41M$155.51M$152.64M$141.63M$146.98M$142.72M$142.77M
    Cash and equivalents$533.99M$117.44M$122.67M$148.59M$183.05M$201.37M$210.44M$221.40M$226.32M$239.14M$243.35M$266.27M
    Shareholder equity$888.02M$445.74M$455.09M$456.10M$472.96M$478.20M$440.11M$455.94M$472.69M$491.14M$560.13M$590.04M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Sep 2026.

    Annual

    Line itemSep 2026Sep 2025Sep 2024Sep 2023Sep 2022Sep 2021Sep 2020Sep 2019Sep 2018Sep 2017
    Operating cash flow-$41.43M-$47.63M-$64.09M-$142.47M-$124.39M-$112.24M-$142.25M-$87.94M-$66.16M-$51.30M
    Capital expenditures$47.58M$28.00M$5.08M$27.78M$101.86M$27.06M$9.87M$14.76M$3.69M$6.59M
    Free cash flow-$89.01M-$75.63M-$69.17M-$170.25M-$226.24M-$139.31M-$152.12M-$102.69M-$69.85M-$57.90M
    Share repurchases$42.00K$16.00K$3.98M$4.41M$7.75M$10.85M$2.42M$0$2.36M$0
    Investing cash flow-$53.09M-$24.76M-$3.07M$50.61M-$232.93M$156.16M-$114.65M-$104.81M$27.31M-$9.99M
    Financing cash flow$446.68M$28.54M$6.89M$911.00K$270.53M$329.18M$303.73M$158.58M$88.82M$63.80M
    Fiscal years ended Sep 2017 to Sep 2026

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$173.00K$1.11M-$17.56M-$24.81M-$11.81M-$1.40M-$12.99M-$21.43M-$15.32M-$6.38M-$19.42M-$22.97M
    Capital expenditures$14.96M$9.76M$12.89M$9.97M$12.43M$9.16M$4.14M$2.27M$2.00M$965.00K$603.00K$1.51M
    Free cash flow-$15.13M-$8.65M-$30.45M-$34.79M-$24.24M-$10.56M-$17.13M-$23.70M-$17.32M-$7.34M-$20.03M-$24.48M
    Last 12 quarters

    Frequently Asked Questions About TWST

    What is Twist Bioscience's annual revenue?

    Twist Bioscience reported revenue of $459.43M for the fiscal year ended Sep 30, 2026.

    How fast is Twist Bioscience's revenue growing?

    Revenue was up 22.0% for the fiscal year ended Sep 30, 2026 compared with the year before. The compound annual revenue growth rate over 3 years was 23.3%.

    Is Twist Bioscience profitable?

    No. Twist Bioscience reported net income of -$130.20M for the fiscal year ended Sep 30, 2026, with a net margin of -28.3%.

    How much free cash flow does TWST generate?

    For the fiscal year ended Sep 30, 2026, operating cash flow of -$41.43M minus capital expenditures of $47.58M produced free cash flow of -$89.01M.

    How much debt does Twist Bioscience have?

    The balance sheet dated Sep 30, 2026 reported cash and equivalents of $533.99M.